Navigation Links
Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
Date:2/2/2009

WALTHAM, Mass., Feb. 2 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at the BIO CEO and Investor Conference on Monday, February 9th, 2009 at 11:30 a.m. EST at the Waldorf-Astoria Hotel, 301 Park Avenue, New York, NY.

A live audio webcast of the presentation will be available via Repligen's website at www.repligen.com and will be archived for 30 days following the presentation.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, pla
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... According to new market research ... Types (Colocation, Enterprise, Telecom), by Design Types (Electrical, ... 2, Tier 3, Tier 4) - Global Forecast ... the Data Center Construction Market into various segments ... This research report also identifies the factors driving ...
(Date:10/25/2014)... 2014 SonaCare Medical, LLC, leader ... technology, announced that its Board of Directors has ... Officer, President and member of the Board effective ... take-on expanded responsibilities within the company, including further ... overseeing commercialization, manufacturing and finance. , Dr. ...
(Date:10/25/2014)... Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") today ... on Thymosins in Health and Disease in ... beta 4 (TB4) linked with rhodamine (a fluorescent tracer ... rodent model of stroke, it was visualized outside of ... tissue of the brain).   The leakage of TB4 in ...
(Date:10/22/2014)... -- Research and Markets has announced ... Market (Product types, Application, Technology, End User and ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... offering. This new report titled, ... and Geography) Global Size, Industry Analysis, Trends, Opportunities, ...
Breaking Biology Technology:Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3
... recent report that probably went unnoticed outside the academic ... released figures that show why the rest of us ... for scientific research. The numbers demonstrate that investment in ... it's about creating jobs for the 21st century economy. ...
... Technical College would like to see more women going into ... women in IT careers has declined from a high of 41 ... And at MATC, enrollment of women in IT programs has dropped ... IT Expo at the college on Wednesday was Patricia Prime, ...
... . and Imaxio S.A. (Saint-Beauzire, France) have ... manufacture and sell OverExpress bacterial cells for ... retain the right to license the use of OverExpress ... cells to commercial licensees. No license will be required ...
Cached Biology Technology:Tapping hidden assets: Wisconsin researchers who can create jobs 2Tapping hidden assets: Wisconsin researchers who can create jobs 3Tapping hidden assets: Wisconsin researchers who can create jobs 4MATC seeks to turn around falling tech enrollment among women 2Lucigen Corp. enters global licensing agreement 2
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
(Date:10/15/2014)... linked increased resistance to bacterial pneumonia in female mice ... estrogen. , Females are naturally more resistant to respiratory ... has shown that increased resistance to bacterial pneumonia in ... synthase 3 (NOS3). They also show that this enzyme ... sex hormone estrogen. , The team, lead by Professor ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to ... the development of skin cancers by turning on an ... skin cells. , Previously considered protective, SIRT6 is part ... help regulate genomic stability and prevent some of the ... damage, which can lead to cancer. This study, in ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... Mass. Joshua Kritzer, assistant professor in the School ... University, has been awarded one of 33 NIH Director,s ... awarded by the National Institutes of Health. The ... to support unusually creative new investigators with highly innovative ...
... -- November 12, 2010 --Canadian biologist Chris Wood was ... Science. The Award was presented by Dr. Philip Campbell, ... for Graduate Studies annual meeting in Toronto earlier this ... Royal Society of Canada, is a professor in the ...
... Powdery mildew is a fungus that infects both crop and ... cause immense crop loss. Despite decades of intense research, little ... to invade the host,s epidermal cells. A European research group ... of Zurich, now published a study in Science ...
Cached Biology News:Tufts University chemist earns prestigious award for promising research on drug development 2Nature honors outstanding faculty mentor 2Fertility or powdery mildew resistance? 2Fertility or powdery mildew resistance? 3
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
... incorporating the sophisticated DirectDrive architecture and ... Varian NMR System is undeniably the ... Varian NMR System features parallel controllers ... providing pulse sequence programming power with ...
... Anti-HMGN2/HMG-17 Immunogen : Recombinant ... pH7.4, 5mg/ml BSA, 0.15M NaCl, ... addition of glycerol to 30% ... immunoblot on acid extracts of ...
Luminometers...
Biology Products: